HomeBUSINESS
BUSINESS

Teijin Earns Japan Rights to Novel Botulinum Toxin
(Oct.13.2017)

Teijin said on October 12 that it has obtained rights in Japan to codevelop and exclusively commercialize Xeomin (incobotulinumtoxin A), a novel type A botulinum neurotoxin being developed by Germany’s Merz Pharma ...
(LOG IN FOR FULL STORY)

News Calendar